 |
Limited Coverage Drugs - Special Authority Criteria
| Generic Name / Strength / Form |
| risedronate 30mg |
| Criteria |
Approval Period |
Diagnosis of Paget's disease
PLUS
an adequate trial of etidronate that has failed to reduce symptoms and/or has not reduced levels of alkaline phosphatase |
Indefinite |
Practitioner Exemptions
- No practitioner exemptions
Special Notes
- Adequate trial is defined as at least two months of etidronate therapy.
Online Forms (PDF)
Click on the link to complete a special authority request form.
PDF Format
Some documents on this Web site are in PDF format and require a PDF reader. If you do not have Adobe Acrobat Reader Version 7.0 or the most recent version of another PDF reader, you can download Adobe Acrobat Reader by selecting the 'Get Acrobat Reader' icon.
Last Revised: June 21, 2006
|
